

Onconova Therapeutics, Inc.

Form 4

August 01, 2013

FORM 4**UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549**

Check this box
if no longer
subject to
Section 16.
Form 4 or
Form 5
obligations
may continue.
See Instruction
1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF
SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,
Section 17(a) of the Public Utility Holding Company Act of 1935 or Section
30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB
Number: 3235-0287
Expires: January 31,
2005
Estimated average
burden hours per
response... 0.5

(Print or Type Responses)

1. Name and Address of Reporting Person *
MEHTA VIREN

(Last) (First) (Middle)

C/O ONCONOVA
THERAPEUTICS, INC., 375
PHEASANT RUN

(Street)

NEWTOWN, PA 18940

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading
Symbol
Onconova Therapeutics, Inc.
[ONTX]

3. Date of Earliest Transaction
(Month/Day/Year)
07/30/2013

4. If Amendment, Date Original
Filed(Month/Day/Year)

5. Relationship of Reporting Person(s) to
Issuer

(Check all applicable)

☒ Director ☐ 10% Owner
☐ Officer (give title below) ☐ Other (specify below)

6. Individual or Joint/Group Filing(Check
Applicable Line)
☒ Form filed by One Reporting Person
☐ Form filed by More than One Reporting
Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	07/30/2013		C	(A) or (D) Amount 73,839 (2)	Price 85,479 (2)	D	
Common Stock	07/30/2013		C	7,686 A (8)	93,165 (2)	D	
Common Stock	07/30/2013		C	17,082 (10) A (9)	110,247 (2) (10)	D	
Common Stock	07/30/2013		P	16,667 A \$ 15	126,914 (2) (10)	D	
	07/30/2013		C	6,768 A (1)	6,768	I	

Edgar Filing: Onconova Therapeutics, Inc. - Form 4

Common Stock								By Viram Foundation ⁽³⁾
Common Stock	07/30/2013	C	772	A	<u>(6)</u>	7,540	I	By Viram Foundation ⁽³⁾
Common Stock	07/30/2013	C	755	A	<u>(7)</u>	8,295	I	By Viram Foundation ⁽³⁾
Common Stock	07/30/2013	C	4,632	A	<u>(1)</u>	4,632	I	By Mehta Partners LLC ⁽⁴⁾
Common Stock	07/30/2013	C	1,702	A	<u>(6)</u>	6,334	I	By Mehta Partners LLC ⁽⁴⁾
Common Stock	07/30/2013	C	1,722	A	<u>(7)</u>	8,056	I	By Mehta Partners LLC ⁽⁴⁾
Common Stock	07/30/2013	C	1,050	A	<u>(1)</u>	1,050	I	By Mehta Partners LLC FBO Jean Kiss Marie IRA ⁽⁵⁾
Common Stock	07/30/2013	C	345	A	<u>(6)</u>	1,395	I	By Mehta Partners LLC FBO Jean Kiss Marie IRA ⁽⁵⁾
Common Stock	07/30/2013	C	338	A	<u>(7)</u>	1,733	I	By Mehta Partners LLC FBO Jean Kiss Marie IRA ⁽⁵⁾

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474
(9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

Edgar Filing: Onconova Therapeutics, Inc. - Form 4

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)		8. Amount or Number of Shares
				Code	V (A) (D)	Date Exercisable	Expiration Date	Title		
Series B Convertible Preferred Stock	<u>(1)</u>	07/30/2013		C	87,470 <u>(11)</u>	<u>(1)</u>	<u>(1)</u>	Common Stock		73,839 <u>(2)</u>
Series E Convertible Preferred Stock	<u>(8)</u>	07/30/2013		C	10,246	<u>(8)</u>	<u>(8)</u>	Common Stock		7,686
Series I Convertible Preferred Stock	<u>(9)</u>	07/30/2013		C	22,771 <u>(12)</u>	<u>(9)</u>	<u>(9)</u>	Common Stock		17,082 <u>(12)</u>
Series B Convertible Preferred Stock	<u>(1)</u>	07/30/2013		C	8,020	<u>(1)</u>	<u>(1)</u>	Common Stock		6,768
Series C Convertible Preferred Stock	<u>(6)</u>	07/30/2013		C	1,030	<u>(6)</u>	<u>(6)</u>	Common Stock		772
Series D Convertible Preferred Stock	<u>(7)</u>	07/30/2013		C	1,007	<u>(7)</u>	<u>(7)</u>	Common Stock		755
Series B Convertible Preferred Stock	<u>(1)</u>	07/30/2013		C	5,488	<u>(1)</u>	<u>(1)</u>	Common Stock		4,632
Series C Convertible Preferred Stock	<u>(6)</u>	07/30/2013		C	2,270	<u>(6)</u>	<u>(6)</u>	Common Stock		1,702
Series D Convertible Preferred Stock	<u>(7)</u>	07/30/2013		C	2,296	<u>(7)</u>	<u>(7)</u>	Common Stock		1,722

Series B Convertible Preferred Stock	<u>(1)</u>	07/30/2013	C	1,245	<u>(1)</u>	<u>(1)</u>	Common Stock	1,050
Series C Convertible Preferred Stock	<u>(6)</u>	07/30/2013	C	460	<u>(6)</u>	<u>(6)</u>	Common Stock	345
Series D Convertible Preferred Stock	<u>(7)</u>	07/30/2013	C	451	<u>(7)</u>	<u>(7)</u>	Common Stock	338

Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
MEHTA VIREN C/O ONCONOVA THERAPEUTICS, INC. 375 PHEASANT RUN NEWTOWN, PA 18940			X	

Signatures

/s/ Ajay Bansal, as attorney
in fact 07/30/2013

__Signature of Reporting Person

Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The Series B Convertible Preferred Stock converted into Common Stock on a 0.85-for-1 basis and had no expiration date.
- (2) Includes 11,356 shares held jointly with spouse.
- (3) The reporting person is a trustee of the Viram Foundation
- (4) The reporting person is managing member of Mehta Partners LLC
- (5) The reporting person is trustee of Mehta Partners LLC FBO Jean Kiss Marie IRA.
- (6) The Series C Convertible Preferred Stock converted into Common Stock on a 0.75-for-1 basis and had no expiration date.
- (7) The Series D Convertible Preferred Stock converted into Common Stock on a 0.75-for-1 basis and had no expiration date.
- (8) The Series E Convertible Preferred Stock converted into Common Stock on a 0.75-for-1 basis and had no expiration date.

Edgar Filing: Onconova Therapeutics, Inc. - Form 4

- (9) The Series I Convertible Preferred Stock converted into Common Stock on a 0.75-for-1 basis and had no expiration date.
- (10) Includes 17,082 shares held jointly with spouse.
- (11) Includes 13,454 shares held jointly with spouse.
- (12) Shares held jointly with spouse.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.